Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754171 | 0.93 | MEN1 (0.37) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17753869 | 0.88 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17752175 | 0.84 | MEN1 (0.47) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17778355 | 0.82 | MAPT (0.36) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17754186 | 0.82 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1L3MBTL1CA9 | |
| SCHEMBL5001405 | 0.80 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17778353 | 0.80 | CYP17A1 (0.38) | MEN1KMT2AALDH1A1MAPTATM | |
| SCHEMBL17753844 | 0.80 | — | — | |
| SCHEMBL17754185 | 0.79 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL17753843 | 0.79 | TSHR (0.33) | ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9971241-B2 | Compound, resin, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160139508-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139508-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | AFF1, AFF2, AFF4 | MEN1 4160/4885KMT2A 1454/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.